MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-05-2024
Nektar Therapeutics DPO Ratio 2011-2026 | NKTR
Annual DPO Ratio Nektar Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123 | 192 | 234 | 388 | 328 | 87.5 | 57.1 | 34 | 25.3 | 34.6 | 86.4 | 34.3 | 50.3 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 388 | 25.3 | 129 |
Quarterly DPO Ratio Nektar Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 48.9 | - | 192 | 247 | 372 | 251 | 353 | 467 | 363 | 350 | 495 | 293 | 356 | 350 | 210 | 71.6 | 112 | 96.7 | 73 | 44.7 | 76.9 | 48.5 | 56.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 495 | 44.7 | 224 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Happiness Biotech Group Limited
HAPP
|
5.06 K | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
5.24 K | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
AstraZeneca PLC
AZN
|
265 | - | - | $ 96.9 B |  Britain |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M | Britain |
 |
Esperion Therapeutics
ESPR
|
7.93 K | $ 3.13 | - | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
74.3 | $ 32.59 | -6.89 % | $ 877 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Celyad Oncology SA
CYAD
|
55.8 K | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
135 | - | -7.31 % | $ 87 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
9.57 | $ 1.7 | 3.03 % | $ 452 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
Heron Therapeutics
HRTX
|
91.4 | $ 0.86 | -1.42 % | $ 143 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
1.79 K | - | -4.36 % | $ 27 M | USA |
 |
Compugen Ltd.
CGEN
|
82.7 | $ 2.8 | 7.28 % | $ 262 M | Israel |
 |
Anika Therapeutics
ANIK
|
43.4 | $ 14.88 | -0.93 % | $ 213 M | USA |
 |
Advaxis
ADXS
|
85.6 K | - | -9.65 % | $ 45.9 M | USA |
 |
Incyte Corporation
INCY
|
200 | $ 97.16 | -0.26 % | $ 19 B | USA |
 |
Ionis Pharmaceuticals
IONS
|
815 | $ 75.56 | -0.29 % | $ 12.1 B | USA |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M |  Canada |
 |
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Coherus BioSciences
CHRS
|
507 | $ 1.61 | 2.55 % | $ 189 M | USA |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
133 | $ 20.86 | -0.71 % | $ 2.65 B | USA |